New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically relevant orthotopic model; Further ...
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi ...
CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, announced significant preclinical results for their new drug candidate ...
Silexion Therapeutics Corp. announced that it will present a poster at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco, scheduled for January 23-25, 2025. The presentation will ...
Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...
NEW YORK--(BUSINESS WIRE)--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback